Publish in this journal
Journal Information
Vol. 17. Issue 4.
Pages 203-206 (April 2021)
Download PDF
More article options
Vol. 17. Issue 4.
Pages 203-206 (April 2021)
Original Article
DOI: 10.1016/j.reumae.2020.02.002
Secukinumab as biological treatment for psoriatic arthritis in real clinical practice
Secukinumab como tratamiento biológico en la artritis psoriásica en práctica clínica real
José A. Pinto Tasendea,
Corresponding author
, Francisco J. Maceiras Panb, José A. Mosquera Martínezc, Luis Fernández Dominguezd, Blanca Correa Reye, Carlos García Porrúaf
a Servicio de Reumatología, Centro Hospitalario Universitario A Coruña-INIBIC, La Coruña, Spain
b Servicio de Reumatología, Centro Hospitalario Universitario de Vigo, Vigo, Spain
c Servicio de Reumatología, Hospital Universitario de Pontevedra, Pontevedra, Spain
d Servicio de Reumatología, Hospital Universitario de Ourense, Orense, Spain
e Servicio de Reumatología, Hospital Universitario de Ferrol, Ferrol, Spain
f Servicio de Reumatología, Hospital Universitario Lucus Augusti, Lugo, Spain
Article information
Full Text
Download PDF
Figures (2)
Tables (2)
Table 1. Basal characteristics of the patients treated with secukinumab (naive and not naive to biological drugs).
Table 2. Data on efficacy and safety over 12 months according to dose.
Show moreShow less

Clinical trials of secukinumab have demonstrated their efficacy and safety in psoriatic arthritis as biological first choice or after inadequate response to other biological treatments.


To analyze the efficacy and safety of secukinumab in peripheral psoriatic arthritis over 12 months in real clinical practice.

Material and methods

Patients with active peripheral psoriatic arthritis who started treatment with secukinumab according to the technical specifications were included. Efficacy and safety were evaluated from baseline to 12 months comparing naive and non-naive to biological therapy patients.


76 patients were included (22 naive and 54 non-naive to biological) with an age of 51.9 years (10.3) and duration of the disease of 9.5 years (7.1). 31.6% with dactylitis, 51.3% with enthesitis and the baseline DAPSA was 19.0 (9.8). The retention rate was high, 90.9% in naive and 81.5% in non-naïve patients, and the percentage of patients with a DAPSA less than or equal to 14 was higher in the naive patients even after adjusting for age, sex and FAMEsc (p = .016). The safety data were similar to those described in the clinical trials.


Secukinumab is effective and safe in 12-month treatment in peripheral active PsA in real clinical practice, after inadequate response to TNF or as first biological treatment.

Psoriatic arthritis
Adverse effects

Los ensayos clínicos de secukinumab han demostrado su eficacia y seguridad en la artritis psoriásica como biológico de primera opción o tras respuesta inadecuada a otros tratamientos biológicos.


Analizar la eficacia y seguridad de secukinumab en la artritis psoriásica periférica durante 12 meses en práctica clínica real.

Material y métodos: Se incluyeron pacientes con artritis psoriásica periférica activa que iniciaron tratamiento con secukinumab según ficha técnica. Se evaluó la eficacia y seguridad desde la basal hasta los 12 meses comparando pacientes naive y no naive a biológico.


Se incluyeron 76 pacientes (22naive y 54 no naive a biológico) con una edad de 51,9 años (10,3) y duración de la enfermedad de 9,5 años (7,1). El 31.6% con dactilitis, 51.3% con entesitis y el DAPSA basal fue 19 (9,8). La tasa de retención fue elevada, 90,9 % en naive y 81,5 % en no naive, y el porcentaje de pacientes con un DAPSA menor o igual a 14 fue mayor en pacientes naive, incluso después de ajustar por edad, sexo y FAMEsc p = 0,016. Los datos de seguridad fueron similares a los descritos en los ensayos clínicos.


Secukinumab es eficaz y seguro en el tratamiento a 12 meses en la APs periférica activa en la práctica clínica real, tras respuesta inadecuada a los iTNF o como primer biológico.

Palabras clave:
Artritis psoriásica
Acontecimientos adversos


These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Reumatología Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?